News & Events

Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLC

Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLC

Krascendo 1 results answer ‘important question’ in KRAS G12C-mutated NSCLC

Krascendo 1 results answer ‘important question’ in KRAS G12C-mutated NSCLC

Krascendo 1 results answer ‘important question’ in KRAS G12C-mutated NSCLC

Krascendo 1 results answer ‘important question’ in KRAS G12C-mutated NSCLC

KRAS Inhibitor Resistance in Lung Cancer: Mechanisms and Therapeutic Opportunities

KRAS Inhibitor Resistance in Lung Cancer: Mechanisms and Therapeutic Opportunities

Dr Negrao on Olomorasib Plus Chemoimmunotherapy in KRAS G12C–Mutant NSCLC

Dr Negrao on Olomorasib Plus Chemoimmunotherapy in KRAS G12C–Mutant NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

2026 ESMO丨全新一代KRAS G12C抑制剂:Divarasib以III期头对头全面获益,彰显KRAS G12C突变NSCLC后线治疗同类最佳潜力_腾讯新闻

2026 ESMO丨全新一代KRAS G12C抑制剂:Divarasib以III期头对头全面获益,彰显KRAS G12C突变NSCLC后线治疗同类最佳潜力_腾讯新闻

New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC

New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC